106 related articles for article (PubMed ID: 14610217)
1. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells.
Zhang T; Fields JZ; Ehrlich SM; Boman BM
J Pharmacol Exp Ther; 2004 Feb; 308(2):434-7. PubMed ID: 14610217
[TBL] [Abstract][Full Text] [Related]
2. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Calviello G; Resci F; Serini S; Piccioni E; Toesca A; Boninsegna A; Monego G; Ranelletti FO; Palozza P
Carcinogenesis; 2007 Jun; 28(6):1202-9. PubMed ID: 17183061
[TBL] [Abstract][Full Text] [Related]
3. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.
Seo SK; Lee HC; Woo SH; Jin HO; Yoo DH; Lee SJ; An S; Choe TB; Park MJ; Hong SI; Park IC; Rhee CH
Apoptosis; 2007 Jan; 12(1):195-209. PubMed ID: 17136320
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells.
Sakoguchi-Okada N; Takahashi-Yanaga F; Fukada K; Shiraishi F; Taba Y; Miwa Y; Morimoto S; Iida M; Sasaguri T
Biochem Pharmacol; 2007 May; 73(9):1318-29. PubMed ID: 17270149
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin.
Jin HO; Yoon SI; Seo SK; Lee HC; Woo SH; Yoo DH; Lee SJ; Choe TB; An S; Kwon TJ; Kim JI; Park MJ; Hong SI; Park IC; Rhee CH
Biochem Pharmacol; 2006 Nov; 72(10):1228-36. PubMed ID: 16950207
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription.
Torres VA; Tapia JC; Rodriguez DA; Lladser A; Arredondo C; Leyton L; Quest AF
Mol Cell Biol; 2007 Nov; 27(21):7703-17. PubMed ID: 17785436
[TBL] [Abstract][Full Text] [Related]
7. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.
Scheper MA; Nikitakis NG; Sauk JJ
Int J Oral Maxillofac Surg; 2007 Jul; 36(7):632-9. PubMed ID: 17566705
[TBL] [Abstract][Full Text] [Related]
8. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH
Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453
[TBL] [Abstract][Full Text] [Related]
11. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer.
Zhang T; Otevrel T; Gao Z; Gao Z; Ehrlich SM; Fields JZ; Boman BM
Cancer Res; 2001 Dec; 61(24):8664-7. PubMed ID: 11751382
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.
Rice PL; Beard KS; Driggers LJ; Ahnen DJ
Cancer Res; 2004 Nov; 64(22):8148-51. PubMed ID: 15548677
[TBL] [Abstract][Full Text] [Related]
13. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
Ai Z; Yin L; Zhou X; Zhu Y; Zhu D; Yu Y; Feng Y
Cancer; 2006 Aug; 107(4):746-56. PubMed ID: 16826583
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
16. COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin down-regulation.
Scheper MA; Sauk JJ; Nikitakis NG
Anticancer Res; 2006; 26(6B):4103-13. PubMed ID: 17201121
[TBL] [Abstract][Full Text] [Related]
17. Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC.
Chang WC; Everley LC; Pfeiffer GR; Cooper HS; Barusevicius A; Clapper ML
Ann N Y Acad Sci; 2005 Nov; 1059():41-55. PubMed ID: 16382042
[TBL] [Abstract][Full Text] [Related]
18. Roles of survivin isoforms in the chemopreventive actions of NSAIDS on colon cancer cells.
Mandayam S; Huang R; Tarnawski AS; Chiou SK
Apoptosis; 2007 Jun; 12(6):1109-16. PubMed ID: 17151952
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.
Wang J; Yang L; Yang J; Kuropatwinski K; Wang W; Liu XQ; Hauser J; Brattain MG
Cancer Res; 2008 May; 68(9):3152-60. PubMed ID: 18451140
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
